IsoPlexis Wins $2M SBIR Grant From NCI

Single-cell proteomics firm IsoPlexis said today it has received a $2 million grant from the National Cancer Institute’s Small Business Innovation Research (SBIR) Development Center. The grant will fund development of methods using the company’s IsoLight system to study protein signaling pathways in single tumor cells, allowing for improved analysis of cancer signaling and tumor heterogeneity.

2019-10-24T14:25:29-05:00